Table 3.

Summary of key recommendations

New research studies should include:

1. Standardized measures for clinical and patient reported outcomes:

Clinical outcomes can be reported as sputum conversion rate or cure and mortality rates at the end of treatment

A range of patient-reported measures can be used: PREMs, PROMs, QALY, MOS-HIV Health Survey, and Karnofsky score

2. Person-centered framework that acknowledges different comorbidities and treatment adverse events

3. Strategies to minimize toxicity (e.g., intermittent administration)

4. Cost-effectiveness and cost–benefit assessment

In addition, new research studies should enable:

5. Data registries on clinical relevance and patient’s treatment and outcome to be commenced and easily populated

6. Epidemiological/surveillance data on likelihood of adverse events to be made easily available to patients and health-care providers

Definition of abbreviations: MOS-HIV = Medical Outcomes Study HIV; PREMS = patient-reported experience measures; PROMS = patient-reported outcome measures; QALY = quality-adjusted life years.